Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Breast Cancer
Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancers

Interventions

DRUG: BNT327 Dose Level 1 (DL1)
DRUG: BNT327 Dose Level 1 (DL2)
DRUG: Nab-placlitaxel
DRUG: Carboplatin
DRUG: Gemcitabine
DRUG: Paclitaxel
DRUG: Eribulin
DRUG: BNT327 Optimized Dose
DRUG: BNT327 Equivalent Q3W Dose

Sponsor

BioNTech SE

Collaborators

[object Object]